Comparison of febuxostat and allopurinol for hyperuricemia in cardiac surgery patients (NU-FLASH trial)

Circulation Journal

Volumn 77, Issue 8, 2013, Pages 2043-2049

  Sezai, Akira ^a   Soma, Masayoshi ^b   Nakata, Kin Ichi ^a   Hata, Mitsumasa ^a   Yoshitake, Isamu ^a   Wakui, Shinji ^a   Hata, Hiroaki ^a   Shiono, Motomi ^a  

^a Institute of DNA Medicine   (Japan)

^b NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Allopurinol; Febuxostat; Hyperuricemia

Indexed keywords

ALBUMIN; ALLOPURINOL; C REACTIVE PROTEIN; CHOLESTEROL; CREATININE; CYSTATIN C; FEBUXOSTAT; ICOSAPENTAENOIC ACID; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; URIC ACID;

AGED; ARTICLE; BLOOD PRESSURE; FEMALE; GOUT; HEART EJECTION FRACTION; HEART LEFT VENTRICLE MASS; HEART RATE; HEART SURGERY; HUMAN; HYPERURICEMIA; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PULSE WAVE; SIDE EFFECT;

AGED; ALBUMINURIA; ALLOPURINOL; ARACHIDONIC ACID; BLOOD PRESSURE; C-REACTIVE PROTEIN; CARDIAC SURGICAL PROCEDURES; CHOLESTEROL; CREATININE; CYSTATIN C; FEMALE; GOUT SUPPRESSANTS; HUMANS; HYPERURICEMIA; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; PULSE WAVE ANALYSIS; STROKE VOLUME; THIAZOLES; URIC ACID;

EID: 84880778263     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-13-0082     Document Type: Article

References (25)

1. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. JAMA 2003; 289: 2560-2572.
2. Park SH, Shin WY, Lee EY, Gil HW, Lee SW, Lee SJ, et al. The impact of hyperuricemia on in-hospital mortality and incidence of acute kidney injury in patients undergoing percutaneous coronary intervention. Circ J 2011; 75: 692-697.
3. Kansui Y, Ohtsubo T, Goto K, Sakata S, Ichishima K, Fukuhara M, et al. Association of serum uric acid with blood pressure in Japanese men: Cross-sectional study in work-site group. Circ J 2011; 75: 2827-2832.
4. Fagugli RM, Gentile G, Ferrara G, Brugnano R. Acute renal and hepatic failure associated with allopurinol treatment. Clin Nephrol 2008; 70: 523-526.
5. Halevy S, Ghislain PD, Mockenhaupt M, Fagot JP, Bouwes Bavinck JN, Sidoroff A, et al. Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol 2008; 58: 25-32.
6. Becker MA, Schumacher HR, Wortmann RL, MacDonald PA, Eustace D, Palo WA, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005; 353: 2450-2461.
7. Okamoto K, Eger BT, Nishino T, Kondo S, Pai EF, Nishino T. An extremely potent inhibitor of xanthine oxidoreductase: Crystal structure of the enzyme-inhibitor complex and mechanism of inhibition. J Biol Chem 2003; 278: 1848-1855.
8. Matsumoto K, Okamoto K, Ashizawa N, Nishino T. FYX-051: A novel and potent hybrid-type inhibitor of xanthine oxidoreductase. J Pharmacol Exp Ther 2011; 336: 95-103.
9. Burns CM, Wortmann RL. Gout therapeutics: New drugs for an old disease. Lancet 2011; 377: 165-177.
10. Tatuo H, Iwao O. A repeated oral administration study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase in patients with impaired renal function in Japan. J Clin Rheumatol 2011; 17: S27-S34.
11. Kamatani N, Fujimori S, Hada T, Hosoya T, Kohri K, Nakamura T, et al. Multicenter, open-label study of long-term administration of febuxostat (TMX-67) in Japanese patients with hyperuricemia including gout. J Clin Rheumatol 2011; 17: S50-S56.
12. Siu Y, Leung, K, Tong MK, Kwan T. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis 2006; 47: 51-59.
13. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009; 53: 982-992.
14. Goicoechea M, de Vinuesa SG, Verdalles U, Ruiz-Caro C, Ampuero J, Rincon A, et al. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol 2010; 5: 1388-1393.
15. Whelton A, Macdonald PA, Zhao L, Hunt B, Gunawardhana L. Renal function in gout: Long-term treatment effects of febuxostat. J Clin Rheumatol 2011; 17: 7-13.
16. Peralta CA, Shlipak MG, Judd S, Cushman M, McClellan W, Zakai NA, et al. Detection of chronic kidney disease with creatinine, cys-tatin C, and urine albumin-to-creatinine ratio and association with progression to end-stage renal disease and mortality. JAMA 2011; 305: 1545-1552.
17. Malik UZ, Hundley NJ, Romero G, Radi R, Freeman BA, Tarpey MM, et al. Febuxostat inhibition of endothelial-bound XO: Implications for targeting vascular ROS production. Free Radic Biol Med 2011; 51: 179-184.
18. Rajendra NS, Ireland S, George J, Belch JJF, Lang CC, Struthers AD. Mechanistic insights into the therapeutic use of high-dose al-lopurinol in angina pectoris. J Am Coll Cardiol 2011; 58: 820-828.
19. Anderson SG, Sanders TA, Cruickshank K. Plasma fatty acid composition as a predictor of arterial stiffness and mortality. Hypertension 2009; 53: 839-845.
20. Khan F, George J, Wong K, McSwiggan S, Struthers AD, Belch JF. The association between serum urate levels and arterial stiffness/ endothelial function in stroke survivors. Atherosclerosis 2008; 200: 374-379.
21. Noman A, Ang DS, Ogston S, Lang CC, Struthers AD. Effect of high-dose allopurinol on exercise in patients with chronic stable angina: A randomised, placebo controlled crossover trial. Lancet 2010; 375: 2161-2167.
22. Kao MP, Ang DS, Gandy SJ, Nadir MA, Houston JG, Lang CC, et al. Allopurinol benefts left ventricular mass and endothelial dysfunction in chronic kidney disease. J Am Soc Nephrol 2011; 22: 1382-1389.
23. Hirsch GA, Bottomley PA, Gerstenblith G, Weiss RG. Allopurinol acutely increases adenosine triphosphate energy delivery in failing human hearts. J Am Coll Cardiol 2012; 59: 802-808.
24. Stone PH. Allopurinol: A new anti-ischemic role for an old drug. J Am Coll Cardiol 2011; 58: 829-830.
25. Opie LH. Allopurinol for heart failure: Novel mechanisms. J Am Coll Cardiol 2012; 59: 809-812.